- Home
- MNPR vs PACB Comparison
MNPR vs PACB Comparison
Compare MNPR & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | PACB |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.4M | 459.0M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | MNPR | PACB |
|---|---|---|
| Price | $61.53 | $1.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $101.42 | $2.10 |
| AVG Volume (30 Days) | 145.1K | ★ 5.5M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.22 |
| Revenue Next Year | N/A | $12.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $26.06 | $0.85 |
| 52 Week High | $105.00 | $2.73 |
Technical Indicators
Market Signals| Indicator | MNPR | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 58.07 | 35.78 |
| Support Level | $50.92 | $1.18 |
| Resistance Level | $89.51 | $1.37 |
| Average True Range (ATR) | 3.09 | 0.09 |
| MACD | 1.10 | -0.01 |
| Stochastic Oscillator | 91.62 | 19.09 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.